SRT-3025 hydrochloride | B2376

SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.

SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.

B2376 | SRT-3025 hydrochloride DataSheet

Alternate Name/Synonyms: 5-(3-methoxypropyl)-2-phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide hydrochloride, SRT3025 HCl

Appearance: Crystalline solid

Formulation:

CAS Number: 2070015-26-6

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₃₁H₃₂ClN₅O₂S₂

Molecular Weight: 606.2

Cell-Permeable?: TRUE

Purity: ≥98% by HPLC

Solubilities: >50 mg/ml in DMSO

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: A potent and selective Sirt1 activator

MDL Number:

PubChem CID: 119000000

SMILES: COCCCC1=C(N=C(S1)C2=CC=CC=C2)C(=O)NC3=CC=CC=C3C4=NC5=C(S4)N=CC(=C5)CN6CCCC6.Cl

InChi: InChI=1S/C31H31N5O2S2.ClH/c1-38-17-9-14-26-27(35-29(39-26)22-10-3-2-4-11-22)28(37)33-24-13-6-5-12-23(24)30-34-25-18-21(19-32-31(25)40-30)20-36-15-7-8-16-36;/h2-6,10-13,18-19H,7-9,14-17,20H2,1H3,(H,33,37);1H from PubChem

InChi Key: LGRBDTOIPNDWMN-UHFFFAOYSA-N